Elevance Health (NYSE: ELV) is one of the largest health benefits companies in the United States. This leading healthcare provider offers a wide range of health insurance products and healthcare services to individuals, employers, and government-sponsored programs. Elevance Health operates through various well-known brands, including Anthem Blue Cross and Blue Shield, and actively competes with other major health insurers in the market.
On April 23, 2026, prominent investment firm Leerink Partners raised its price target for Elevance Health to $364.00 from $357.00. A price target is an analyst's projection of a stock's future price. At the time, the stock was trading at $346.21, meaning the new target represented a potential upside of approximately 5.14% for investors.
This optimistic revision follows Elevance Health's strong first-quarter performance. The company reported quarterly earnings of $12.58 per share, which is significantly higher than the Zacks Consensus Estimate of $10.68 per share. This impressive figure also shows an increase from the $11.97 per share earned in the same quarter of the previous year, highlighting robust earnings growth.
Elevance Health's revenue also surpassed market expectations. The company posted revenues of $49.49 billion, outperforming the consensus estimate by 3.68%. As highlighted by Reuters, Elevance Health also raised its annual profit forecast. This indicates management's confidence in its strategy to keep medical costs under control, which is a key factor for sustained profitability in the competitive insurance industry.
Following these strong results, CEO Gail K. Boudreaux stated that the performance reflects "underlying business strength and improving claims experience," as reported by Business Wire. Elevance Health's market capitalization, which is the total value of all its shares, stands at approximately $76.07 billion, with the stock recently trading at $346.29.
